Table 1 Demographic and clinical characteristics of patients
From: Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series
Characteristic | Patients (N = 8) |
|---|---|
Median age (IQR), years | 60.5 (47.5–68.5) |
Male sex, no. (%) | 4 (50.0) |
Oxygen support, no. (%) | 0 |
Body mass index (kg/m2), median (IQR) | 22.2 (20.0–26.8) |
Median duration of positive RNA detection before favipiravir therapy (days), median (IQR) | 61.0 (52.8–67.3) |
Other therapies before favipiravir therapy, no. (%) | |
 Chloroquine phosphate | 4 (50.0) |
 Umifenovir | 3 (37.5) |
 Entecavir | 1 (12.5) |
 Lianhua Qingwen granules | 2 (25.0) |
 Thymopeptides | 4 (50.0) |
 Pidotimod | 4 (50.0) |
 Plasma transfusion | 2 (25.0) |
Coexisting conditions, no. (%) | |
 Any condition | 6 (75.0) |
 Hypertension | 4 (50.0) |
 Diabetes | 2 (25.0) |
 Coronary heart disease | 1 (12.5) |
 Malignant tumor | 2 (25.0) |
Immunoglobulin level (AU/mL), median (IQR) | |
 IgM | 12.5 (5.1–25.2) |
 IgG | 102.7 (56.1–162.5) |